Kashiv BioSciences Strengthens EU Reach With Intas

Kashiv BioSciences has entered into an exclusive licensing and supply agreement with Intas Pharmaceuticals Ltd, expanding its footprint across Europe, the UK, and India.

The Kashiv BioSciences alliance will aim at commercialization of a complex peptide product in these strategic markets.

Kashiv will be involved in the production of the product, supply, and regulation registration under the agreement. Intas will market the therapy within India and its subsidiary, Accord Healthcare Ltd, will do commercialization and distribution throughout Europe and UK. The agreement is pan-European, UK, and Indian, which enhances the representation of both firms in the demand-driven regions.

Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation

“Our partnership with Intas, leveraging its strong pan-European presence through Accord, enables Kashiv to expand our commercial reach across key European, UK, and Indian markets and strengthen our overall portfolio in the regions,” said Dr. Sandeep Athalye, Global CEO of Kashiv BioSciences. “This collaboration reflects our shared commitment to improving patient outcomes and aligns with our mission to make high-quality, affordable therapies more accessible for patients worldwide.”

“We are pleased to partner with Kashiv BioSciences to expand access to high-quality therapies across Europe, the UK and India. By combining our capabilities, we aim to strengthen our presence and better serve the unmet needs of patients and healthcare professionals,” said Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals.